{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:42:08Z","timestamp":1747154528922,"version":"3.40.5"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ajo.2024.04.015","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T06:34:07Z","timestamp":1714113247000},"page":"241-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Malignancy Risk Associated With the Use of Systemic Immunomodulatory Therapy in the Management of Noninfectious Uveitis"],"prefix":"10.1016","volume":"265","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5029-5316","authenticated-orcid":false,"given":"George N.","family":"Papaliodis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-1257","authenticated-orcid":false,"given":"Yinxi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-8640","authenticated-orcid":false,"given":"Daniel A.","family":"Brill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1575-0819","authenticated-orcid":false,"given":"Lucia","family":"Sobrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-118X","authenticated-orcid":false,"given":"Brian","family":"VanderBeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2024.04.015_bib0001","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/bjo.80.9.844","article-title":"The possible impact of uveitis in blindness: a literature survey","volume":"80","author":"Suttorp-Schulten","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2024.04.015_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2040622310368736","article-title":"The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease","volume":"1","author":"O'Connor","year":"2010","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.ajo.2024.04.015_bib0003","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ajo.2024.04.015_bib0004","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/art.21029","article-title":"An international cohort study of cancer in systemic lupus erythematosus","volume":"52","author":"Bernatsky","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajo.2024.04.015_bib0005","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajo.2024.04.015_bib0006","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ajo.2008.04.035","article-title":"Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence","volume":"146","author":"Kempen","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2024.04.015_bib0007","doi-asserted-by":"crossref","first-page":"b2480","DOI":"10.1136\/bmj.b2480","article-title":"Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study","volume":"339","author":"Kempen","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ajo.2024.04.015_bib0008","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ophtha.2014.08.024","article-title":"Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study","volume":"122","author":"Yates","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.04.015_bib0009","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of Noninfectious uveitis in the United States: a claims-based analysis","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2024.04.015_bib0010","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.ophtha.2020.04.034","article-title":"Risk of noninfectious uveitis with female hormonal therapy in a large healthcare claims database","volume":"127","author":"Sobrin","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.04.015_bib0011","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jamaophthalmol.2018.0642","article-title":"Association of hypovitaminosis D with increased risk of uveitis in a large health care claims database","volume":"136","author":"Sobrin","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2024.04.015_bib0012","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ajo.2024.04.015_bib0021","article-title":"Use of immunosuppression and subsequent cancer incidence: cohort study","volume":"2","author":"Buchanich","year":"2023","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.ajo.2024.04.015_bib0013","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF01875554","article-title":"Information on drug use in the elderly: a comparison of pharmacy, general-practitioner and patient data","volume":"17","author":"Heerdink","year":"1995","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.ajo.2024.04.015_bib0014","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/aje\/kwh038","article-title":"A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women","volume":"159","author":"Boudreau","year":"2004","journal-title":"Am J Epidemiol"},{"year":"2000","series-title":"Validity of Pharmacoepidemiology Drug and Diagnosis Data","key":"10.1016\/j.ajo.2024.04.015_bib0015"},{"key":"10.1016\/j.ajo.2024.04.015_bib0016","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/archopht.126.7.986","article-title":"Identification of patients with diabetic macular edema from claims data: a validation study","volume":"126","author":"Bearelly","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2024.04.015_bib0017","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1161\/CIRCULATIONAHA.106.616219","article-title":"Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction","volume":"113","author":"Gislason","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ajo.2024.04.015_bib0018","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa021134","article-title":"A population-based study of measles, mumps, and rubella vaccination and autism","volume":"347","author":"Madsen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2024.04.015_bib0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jamaophthalmol.2013.577","article-title":"Accuracy of international classification of diseases, ninth revision, clinical modification billing codes for common ophthalmic conditions","volume":"131","author":"Muir","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2024.04.015_bib0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/09286586.2015.1012274","article-title":"Accuracy of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) as a research tool for identification of patients with uveitis and scleritis","volume":"22","author":"Uchiyama","year":"2015","journal-title":"Ophthalmic Epidemiol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424001661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424001661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:10:44Z","timestamp":1724371844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939424001661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":21,"alternative-id":["S0002939424001661"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.04.015","relation":{},"ISSN":["0002-9394"],"issn-type":[{"type":"print","value":"0002-9394"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignancy Risk Associated With the Use of Systemic Immunomodulatory Therapy in the Management of Noninfectious Uveitis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}